Older Adults
Psychedelic research involving older adults is gaining traction, highlighting the potential therapeutic benefits of compounds such as psilocybin and MDMA. Recent studies suggest promising safety profiles and efficacy, paving the way for future clinical applications in this demographic.
What is Older Adults?
Older adults often experience various mental health disorders, such as major depressive disorder and anxiety, which can severely impact their quality of life.
The pathophysiology of these conditions can be complex, involving neurobiological and psychosocial factors, making treatment challenging.
Symptoms of these disorders in older adults may include persistent sadness, loss of interest in social activities, and cognitive decline, which are often exacerbated by isolation and physical health issues.
Current Treatments
Standard-of-care treatments for mental health disorders in older adults include pharmacotherapy (e.g., SSRIs, SNRIs) and psychotherapy, although these may have limited efficacy and significant side effects in this population.
Psychedelic Effect Matrix
Systematic comparison of compound efficacy and evidence levels for Older Adults.
| Compound | Magnitude | Evidence | Consistency |
|---|---|---|---|
| Psilocybin Numerous studies demonstrate significant mental health improvements in elderly patients treated with psilocybin. | Large | High | Consistent |
| MDMA Promising results in reducing anxiety and enhancing therapeutic rapport in older adults with PTSD. | Medium | Moderate | Consistent |
| Ketamine Some evidence supports its efficacy in treatment-resistant depression, but research in older adults is still emerging. | Medium | Moderate | Inconsistent |
Psilocybin and Older Adults
Psilocybin, a naturally occurring psychedelic compound, has shown remarkable efficacy in alleviating symptoms of depression and anxiety among older adults. Clinical trials have demonstrated that a single administration can lead to sustained improvements in emotional well-being and cognitive flexibility, potentially transforming how mental health disorders are treated in the elderly.
MDMA and Older Adults
MDMA, known for its empathogenic effects, may enhance the therapeutic alliance between patients and therapists in a clinical setting. For older adults dealing with trauma-related conditions, MDMA-assisted therapy can facilitate emotional processing, resulting in significant reductions in anxiety and improvement in quality of life.
Key Insights
- 1
Recent systematic reviews indicate that older adults participate less frequently in psychedelic clinical trials, yet when they do, they often show high tolerance and positive responses to treatment.
- 2
Studies suggest psilocybin-assisted therapy can significantly improve mood and cognitive flexibility in older adults suffering from depression.
- 3
Safety data from recent trials indicate a favourable risk-benefit profile for psychedelics in the older population, with few adverse effects reported.
- 4
Psychedelic experiences can enhance emotional resilience, which is particularly beneficial for older adults grappling with loss and existential anxiety.
Industrial Landscape
Key players in the psychedelic research field involve non-profits such as the Multidisciplinary Association for Psychedelic Studies (MAPS) and the Beckley Foundation, alongside pharmaceutical companies exploring psychedelics for therapeutic use.
Quick Indicators
\"Ongoing clinical evaluations are investigating Older Adults as a primary indication for various psychedelic compounds.\"
Key Organizations
4 ConnectedDelix Therapeutics
Delix Therapeutics is harnessing the power of neuroplastogens, a novel class of compounds designed to bring about a new paradigm in brain health therapeutics with treatments intended to be safe, fast-acting, and long-lasting. Through its discovery platform, Delix has identified non-hallucinogenic versions of psychedelic compounds with favorable safety and therapeutic profiles. The company was co-founded in 2019 by David E. Olson and Nick Haft, building upon Olson's discovery at the University of California, Davis, of several novel psychoplastogens that have significant therapeutic potential in preclinical models, without hallucinogenic side effects. Delix's treatments are designed to address the root cause of neuropsychiatric conditions by repairing the underlying synaptic damage through targeted neuroplasticity. To date, the company has synthesized over 2000 novel psychoplastogens, many of which are analogs of known psychedelics such as ibogaine and 5-MeO-DMT. Their lead compound, zalsupindole (DLX-001), produces the same rapid and sustained structural and functional plasticity as ketamine, psilocybin, and DMT, without inducing hallucinations or dissociation. Recent Phase I data have demonstrated that DLX-001 is associated with robust signs of CNS engagement and a favorable safety and tolerability profile, with no serious adverse events reported to date. The company's compounds are tailored for swift neuronal repair and can be taken at-home, providing significant advantages to patients, their loved ones, and healthcare providers. Delix focuses on developing non-hallucinogenic psychoplastogens as scalable alternatives to first-generation hallucinogenic psychoplastogens like ketamine and psilocybin.
MAPS
The description of the stakeholder
Lykos Therapeutics
Longer description of Lykos .. lorem ipsum ..
Leiden University
Leiden University doesn't have a dedicated research centre for psychedelics. However, several staff members from their medical centre and psychology faculty are working with psychedelics. Researchers here are working with other universities including Utrecht University as well as Compass Pathways.
Prominent Researchers
1 LinkedConnected Evidence
The latest clinical data points and verified academic findings associated with Older Adults.